Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 8
1966 3
1967 2
1968 16
1969 9
1970 18
1971 29
1972 25
1973 26
1974 49
1975 56
1976 80
1977 95
1978 96
1979 97
1980 80
1981 105
1982 126
1983 123
1984 146
1985 178
1986 172
1987 154
1988 157
1989 192
1990 217
1991 288
1992 249
1993 344
1994 337
1995 373
1996 383
1997 366
1998 389
1999 350
2000 363
2001 330
2002 298
2003 283
2004 297
2005 340
2006 334
2007 358
2008 298
2009 285
2010 329
2011 324
2012 312
2013 256
2014 281
2015 310
2016 260
2017 270
2018 278
2019 281
2020 238
2021 209
2022 170
2023 138
2024 83

Text availability

Article attribute

Article type

Publication date

Search Results

11,407 results

Results by year

Filters applied: . Clear all
Page 1
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Appel GB, et al. J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15. J Am Soc Nephrol. 2009. PMID: 19369404 Free PMC article. Clinical Trial.
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. ...
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the t …
Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.
Zheng Z, Zhang H, Peng X, Zhang C, Xing C, Xu G, Fu P, Ni Z, Chen J, Xu Z, Zhao MH, Li S, Huang X, Miao L, Chen X, Liu B, He Y, Li J, Liu L, Kadeerbai H, Liu Z, Liu Z. Zheng Z, et al. JAMA Netw Open. 2022 Mar 1;5(3):e224492. doi: 10.1001/jamanetworkopen.2022.4492. JAMA Netw Open. 2022. PMID: 35353167 Free PMC article. Clinical Trial.
IMPORTANCE: Lupus nephritis (LN) is typically treated with intravenous cyclophosphamide (IVCY), which is associated with serious adverse effects. ...
IMPORTANCE: Lupus nephritis (LN) is typically treated with intravenous cyclophosphamide (IVCY), which is associated with serious adve …
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.
Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea S, Dandoy CE, Díaz MÁ, Fuchs E, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri KV, Krem MM, Lazarus HM, Liu H, Ljungman P, Masiarz R, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz R, Romee R, Riches M. Goldsmith SR, et al. Blood. 2021 Jun 10;137(23):3291-3305. doi: 10.1182/blood.2020009362. Blood. 2021. PMID: 33657221 Free PMC article. Clinical Trial.
Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft source and posttransplant cyclophosphamide (PTCy) in CMV infection is unclear. ...
Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor transplantation with posttransplant cyclophosp
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group. van Laar JM, et al. JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368. JAMA. 2014. PMID: 25058083 Free article. Clinical Trial.
From March 2001 to October 2009, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until October 31, 2013. INTERVENTIONS: HSCT vs intravenous pulse cyclophosphamide. MAIN OUTCOMES AND MEASURES: The primary end point was event-free …
From March 2001 to October 2009, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until October 3 …
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.
Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Leavey PJ, et al. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. doi: 10.1200/JCO.21.00358. Epub 2021 Oct 15. J Clin Oncol. 2021. PMID: 34652968 Free PMC article. Clinical Trial.
PURPOSE: The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarc …
PURPOSE: The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophospham
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M, Guegan JP, Spalato-Ceruso M, Peyraud F, Kind M, Vanhersecke L, Le Loarer F, Perret R, Cantarel C, Bellera C, Bessede A, Italiano A. Toulmonde M, et al. Mol Cancer. 2024 Feb 20;23(1):38. doi: 10.1186/s12943-024-01946-8. Mol Cancer. 2024. PMID: 38378555 Free PMC article. Clinical Trial.
JX-594 was administered intratumorally at a dose of 1.10(9) pfu every 2 weeks for up to 4 intra-tumoral administrations. Cyclophosphamide was given orally at 50 mg twice daily in a week-on, week-off schedule, and avelumab was administered at 10 mg/kg biweekly. ...Analysis …
JX-594 was administered intratumorally at a dose of 1.10(9) pfu every 2 weeks for up to 4 intra-tumoral administrations. Cyclophosphamide
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N, Yong M, Burns K, Findlay M, Porter D. Helsby N, et al. Cancer Chemother Pharmacol. 2021 Sep;88(3):533-542. doi: 10.1007/s00280-021-04307-0. Epub 2021 Jun 10. Cancer Chemother Pharmacol. 2021. PMID: 34114066 Clinical Trial.
PURPOSE: Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes. ...CONCLUSION: Comedications may be the cause for this inter-occasion variation in bioactivation of cyclophosphamide
PURPOSE: Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to …
Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide.
Stroda KA, Murphy JD, Hansen RJ, Brownlee L, Atencio EA, Gustafson DL, Lana SE. Stroda KA, et al. Am J Vet Res. 2017 Jul;78(7):862-866. doi: 10.2460/ajvr.78.7.862. Am J Vet Res. 2017. PMID: 28650232 Free PMC article. Clinical Trial.
OBJECTIVE To characterize pharmacokinetics of cyclophosphamide and 4-hydoxycyclophosphamide (4-OHCP) in the plasma of healthy cats after oral, IV, and IP administration of cyclophosphamide. ...Pharmacokinetic parameters were determined from drug concentration-versus …
OBJECTIVE To characterize pharmacokinetics of cyclophosphamide and 4-hydoxycyclophosphamide (4-OHCP) in the plasma of healthy cats af …
Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.
Sugita J, Kuroha T, Ishikawa J, Eto T, Fukushima K, Yokota I, Akashi K, Taniguchi S, Harada M, Teshima T. Sugita J, et al. Bone Marrow Transplant. 2024 Mar;59(3):344-349. doi: 10.1038/s41409-023-02162-6. Epub 2023 Dec 19. Bone Marrow Transplant. 2024. PMID: 38114645 Clinical Trial.
Posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been increasingly used in HLA-haploidentical transplantation and recent studies also demonstrated the efficacy of PTCy in HLA-matched transplantation. ...
Posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been increasingly used in HLA-haploiden …
Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK, Hong PS, Tutsch K, Trump DL. Chan KK, et al. Cancer Res. 1994 Dec 15;54(24):6421-9. Cancer Res. 1994. PMID: 7987837 Clinical Trial.
The pharmacokinetics of cyclophosphamide (CP) and several important metabolites was studied in detail in six patients receiving CP alone and with a radio- and chemosensitizing agent, SR-2508. ...
The pharmacokinetics of cyclophosphamide (CP) and several important metabolites was studied in detail in six patients receiving CP al …
11,407 results
You have reached the last available page of results. Please see the User Guide for more information.